Opioid Treatment Surge Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Jun 5, 2019)
Opioid Treatment Surge Act
This bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.
What just happenedJun 6, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseJun 5, 2019
- Jun 6, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Jun 5, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Jun 5, 2019IntroReferralIntro-H
Introduced in House
- Jun 5, 2019IntroReferral1000
Introduced in House